Differential activation of the calcium/protein kinase C and the canonical β-catenin pathway by Wnt1 and Wnt7a produces opposite effects on cell proliferation in PC12 cells

Journal of Neurochemistry

Volumn 104, Issue 6, 2008, Pages 1588-1598

  Spinsanti, Paola ^b   De Vita, Teresa ^b   Caruso, Alessandra ^b   Melchiorri, Daniela ^b   Misasi, Roberta ^b   Caricasole, Andrea ^c   Nicoletti, Ferdinando ^a,b,d  

^a Department of Human Physiology and Pharmacology ^*  (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Siena Biotech SpA   (Italy)

^d IRCCS NEUROMED   (Italy)

Author keywords

catenin pathway; Calcium protein kinase C pathway; PC12 cells; Proliferation; Wnt1; Wnt7a

Indexed keywords

BETA CATENIN; CALCIUM; CYCLIN D1; CYCLIN E; LITHIUM; PROTEIN DICKKOPF 1; PROTEIN KINASE C; REGULATOR PROTEIN; THYMIDINE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; WNT1 PROTEIN; WNT7A PROTEIN;

ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HETEROLOGOUS EXPRESSION; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; BETA CATENIN; CALCIUM; CELL DIVISION; ENHANCER ELEMENTS (GENETICS); ENZYME INHIBITORS; LUCIFERASES; NEURONS; PC12 CELLS; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS; RATS; SIGNAL TRANSDUCTION; THYMIDINE; TRANSFECTION; TRITIUM; WNT PROTEINS; WNT1 PROTEIN;

EID: 39849094735     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.05111.x     Document Type: Article

References (92)

1. Alvarez A. R., Godoy J. A., Mullendorff K., Olivares G. H., Bronfman M. and Inestrosa N. C. (2004) Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Exp. Cell Res. 297, 186-196.
2. Arellano M. and Moreno S. (1997) Regulation of CDK/cyclin complexes during the cell cycle. Int. J. Biochem. Cell Biol. 29, 559-573.
3. Arendt T., Holzer M., Gartner U. and Bruckner M. K. (1998) Aberrancies in signal transduction and cell cycle related events in Alzheimer's disease. J. Neural Transm. Suppl. 54, 147-158.
4. Bafico A., Liu G., Yaniv A., Gazit A. and Aaronson S. A. (2001) Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat. Cell Biol. 3, 683-686.
5. Barker N., Morin P. J. and Clevers H. (2000) The Yin-Yang of TCF/betacatenin signaling. Adv. Cancer Res. 77, 1-24.
6. Bettini E., Magnani E. and Terstappen G. C. (2002) Lithium induces gene expression through lymphoid enhancer-binding factor/T-cell factor responsive element in rat PC12 cells. Neurosci. Lett. 317, 50-52.
7. Busciglio J., Lorenzo A., Yeh J. and Yankner B. A. (1995) Beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron 14, 879-888.
8. Calderone A., Jover T., Noh K. M., Tanaka H., Yokota H., Lin Y., Grooms S. Y., Regis R., Bennett M. V. and Zukin R. S. (2003) Ischemic insults derepress the gene silencer REST in neurons destined to die. J. Neurosci. 23, 2112-2121.
9. Cappuccio I., Calderone A., Buscati C. L. et al. (2005) Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is required for the development of ischemic neuronal death. J. Neurosci. 25, 2647-2657.
10. Caricasole A., Ferraro T., Rimland J. M. and Terstappen G. C. (2002) Molecular cloning and initial characterization of the MG61/PORC gene, the human homologue of the Drosophila segment polarity gene Porcupine. Gene 288, 147-157.
11. Caricasole A., Copani A., Caruso A., Caraci F., Iacovelli L., Sortino M. A., Terstappen G. C. and Nicoletti F. (2003a) The Wnt pathway, cell-cycle activation and beta-amyloid: novel therapeutic strategies in Alzheimer's disease? Trends Pharmacol. Sci. 24, 233-238.
12. Caricasole A., Ferraro T., Iacovelli L., Barletta E., Caruso A., Melchiorri D., Terstappen G. C. and Nicoletti F. (2003b) Functional characterization of WNT7A signaling in PC12 cells: interaction with a FZD5 LRP6 receptor complex and modulation by Dickkopf proteins. J. Biol. Chem. 278, 37024-37031.
13. Caricasole A., Copani A., Caraci F., Aronica E., Rozemuller A. J., Caruso A., Storto M., Gaviraghi G., Terstappen G. C. and Nicoletti F. (2004) Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J. Neurosci. 24, 6021-6027.
14. Caricasole A., Bakker A., Copani A., Nicoletti F., Gaviraghi G. and Terstappen G. C. (2005) Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology. Biosci. Rep. 25, 309-327.
15. Chenn A. and Walsh C. A. (2002) Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 297, 365-369.
16. Chou A. H. and Howard B. D. (2002) Inhibition by Wnt-1 or Wnt-3a of nerve growth factor-induced differentiation of PC12 cells is reversed by bisindolylmaleimide-I but not by several other PKC inhibitors. Oncogene 21, 6348-6355.
17. Chou A. H., Zheng S., Itsukaichi T. and Howard B. D. (2000) Wnt-1 inhibits nerve growth factor-induced differentiation of PC12 cells by preventing the induction of some but not all late-response genes. Brain Res. Mol. Brain Res. 77, 232-245.
18. Copani A., Bruno V., Battaglia G., Leanza G., Pellitteri R., Russo A., Stanzani S. and Nicoletti F. (1995) Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol. Pharmacol. 47, 890-897.
19. Copani A., Condorelli F., Caruso A., Vancheri C., Sala A., Giuffrida Stella A. M., Canonico P. L., Nicoletti F. and Sortino M. A. (1999) Mitotic signaling by beta-amyloid causes neuronal death. FASEB J. 13, 2225-2234.
20. Copani A., Condorelli F., Canonico P. L., Nicoletti F. and Sortino M. A. (2001) Cell cycle progression towards Alzheimer's disease. Funct. Neurol. 16, 11-15.
21. Copani A., Hoozemans J. J., Caraci F., Calafiore M., Van Haastert E. S., Veerhuis R., Rozemuller A. J., Aronica E., Sortino M. A. and Nicoletti F. (2006) DNA polymerase-beta is expressed early in neurons of Alzheimer's disease brain and is loaded into DNA replication forks in neurons challenged with beta-amyloid. J. Neurosci. 26, 10949-10957.
22. Cotter D., Kerwin R., al-Sarraji S., Brion J. P., Chadwich A., Lovestone S., Anderton B. and Everall I. (1998) Abnormalities of Wnt signalling in schizophrenia - evidence for neurodevelopmental abnormality. Neuroreport 9, 1379-1383.
23. Dahmen R. P., Koch A., Denkhaus D., Tonn J. C., Sorensen N., Berthold F., Behrens J., Birchmeier W., Wiestler O. D. and Pietsch T. (2001) Deletions of AXIN1, a component of the WNT/ wingless pathway, in sporadic medulloblastomas. Cancer Res. 61, 7039-7043.
24. Darnell J. E. Jr (2002) Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2, 740-749.
25. De Ferrari G. V. and Inestrosa N. C. (2000) Wnt signaling function in Alzheimer's disease. Brain Res. Brain Res. Rev. 33, 1-12.
26. De Ferrari G. V., Chacon M. A., Barria M. I., Garrido J. L., Godoy J. A., Olivares G., Reyes A. E., Alvarez A., Bronfman M. and Inestrosa N. C. (2003) Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol. Psychiatry 8, 195-208.
27. Dickinson M. E., Krumlauf R. and McMahon A. P. (1994) Evidence for a mitogenic effect of Wnt-1 in the developing mammalian central nervous system. Development 120, 1453-1471.
28. Dynlacht B. D. (1997) Regulation of transcription by proteins that control the cell cycle. Nature 11, 149-152.
29. Erdreich-Epstein A. and Shackleford G. M. (1998) Differential expression of Wnt genes in normal and flat variants of PC12 cells, a cell line responsive to ectopic Wnt1 expression. Growth Factors 15, 149-158.
30. Farias G. G., Godoy J. A., Hernandez F., Avila J., Fisher A. and Inestrosa N. C. (2004) M1 muscarinic receptor activation protects neurons from beta-amyloid toxicity. A role for Wnt signaling pathway. Neurobiol. Dis. 7, 337-348.
31. Farias G. G., Godoy J. A., Vazquez M. C., Adani R., Meshulam H., Avila J., Amitai G. and Inestrosa N. C. (2005) The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBUPO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components. Neurobiol. Dis. 18, 176-183.
32. Fuentealba R. A., Farias G., Scheu J., Bronfman M., Marzolo M. P. and Inestrosa N. C. (2004) Signal transduction during amyloid-betapeptide neurotoxicity: role in Alzheimer disease. Brain Res. Brain Res. Rev. 47, 275-289.
33. Fukuchi T., Sakamoto M., Tsuda H., Maruyama K., Nozawa S. and Hirohashi S. (1998) Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res. 15, 3526-3538.
34. Garrido J. L., Godoy J. A., Alvarez A., Bronfman M. and Inestrosa N. C. (2002) Protein kinase C inhibits amyloid beta peptide neurotoxicity by acting on members of the Wnt pathway. FASEB J. 16, 1982-1984.
35. Gordon M. D. and Nusse R. (2006) Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J. Biol. Chem. 281, 22429-22433.
36. Hedgepeth C. M., Conrad L. J., Zhang J., Huang H. C., Lee V. M. and Klein P. S. (1997) Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev. Biol. 185, 82-91.
37. Hendrix N. D., Wu R., Kuick R., Schwartz D. R., Fearon E. R. and Cho K. R. (2006) Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. Cancer Res. 66, 1354-1362.
38. Herrup K., Neve R., Ackerman S. L. and Copani A. (2004) Divide and die: cell cycle events as triggers of nerve cell death. J. Neurosci. 24, 9232-9239.
39. Hirabayashi Y., Itoh Y., Tabata H., Nakajima K., Akiyama T., Masuyama N. and Gotoh Y. (2004) The Wnt/beta-catenin pathway directs neuronal differentiation of cortical neural precursor cells. Development 131, 2791-2801.
40. Huang H., Mahler-Araujo B. M., Sankila A., Chimelli L., Yonekawa Y., Kleihues P. and Ohgaki H. (2000) APC mutations in sporadic medulloblastomas. Am. J. Pathol. 156, 433-437.
41. Hwang D. Y., Cho J. S., Kim C. K., Shim S. B., Jee S. W., Lee S. H., Seo S. J., Choi S. Y. and Kim Y. K. (2006) Changes in presenilin 2- binding Wnt proteins, behavior, amyloid-beta 42, gamma-secretase activity, and testosterone sensitivity in transgenic mice coexpressing tetracycline-controlled transactivator and human mutant presenilin 2. Neuromol. Med. 8, 415-432.
42. Iacovelli L., Bruno V., Salvatore L., Melchiorri D., Gradini R., Caricasole A., Barletta E., De Blasi A. and Nicoletti F. (2002) Native group-III metabotropic glutamate receptors are coupled to the mitogen-activated protein kinase/phosphatidylinositol-3-kinase pathways. J. Neurochem. 82, 216-223.
43. Ikeya M., Lee S. M., Johnson J. E., McMahon A. P. and Takada S. (1997) Wnt signalling required for expansion of neural crest and CNS progenitors. Nature 389, 966-970.
44. Inestrosa N. C., De Ferrari G. V., Garrido J. L., Alvarez A., Olivares G. H., Barria M. I., Bronfman M. and Chacon M. A. (2002) Wnt signaling involvement in beta-amyloid-dependent neurodegeneration. Neurochem. Int. 41, 341-344.
45. Inestrosa N. C., Urra S. and Colombres M. (2004) Acetylcholinesterase (AChE) - amyloid-beta-peptide complexes in Alzheimer's disease. The Wnt signaling pathway. Curr. Alzheimer Res. 1, 249-254.
46. Inestrosa N. C., Godoy J. A., Quintanilla R. A., Koenig C. S. and Bronfman M. (2005) Peroxisome proliferator-activated receptor gamma is expressed in hippocampalneurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res. 304, 91-104.
47. Issack P. S. and Ziff E. B. (1998) Altered expression of helix-loop-helix transcriptional regulators and cyclin D1 in Wnt-1-transformed PC12 cells. Cell Growth Differ. 9, 837-845.
48. Jackson G. R., Wiedau-Pazos M., Sang T. K., Wagle N., Brown C. A., Massachi S. and Geschwind D. H. (2002) Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34, 509-519.
49. Kawano Y. and Kypta R. (2003) Secreted antagonists of the Wnt signalling pathway. J. Cell Sci. 116, 2627-2634.
50. Kikuchi A. (2003) Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci. 94, 225-229.
51. Kohn A. D. and Moon R. T. (2005) Wnt and calcium signaling: betacatenin- independent pathways. Cell Calcium 38, 439-446.
52. de La Coste A., Romagnolo B., Billuart P. et al. (1998) Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl Acad. Sci. USA 21, 8847-8851.
53. Le N. H., van der Bent P., Huls G. et al. (2004) Aberrant polycystin-1 expression results in modification of activator protein-1 activity, whereas Wnt signaling remains unaffected. J. Biol. Chem. 279, 27472-27481.
54. Levi A., Biocca S., Cattaneo A. and Calissano P. (1988) The mode of action of nerve growth factor in PC12 cells. Mol. Neurobiol. 2, 201-226.
55. Li J., Nguyen L., Gleason C., Lotspeich L., Spiker D., Risch N. and Myers R. M. (2004) Lack of evidence for an association between WNT2 and RELN polymorphisms and autism. Am. J. Med. Genet. B Neuropsychiatry Genet. 126, 51-57.
56. Liang H., Chen Q., Coles A. H., Anderson S. J., Pihan G., Bradley A., Gerstein R. and Jurecic R.and. Jones. S. N. (2003) Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4, 349-360.
57. Loh C., Shaw K. T., Carew J., Viola J. P., Luo C., Perrino B. A. and Rao A. (1996) Calcineurin binds the transcription factor NFAT1 and reversibly regulates its activity. J. Biol. Chem. 271, 10884-10891.
58. Lu W., Yamamoto V., Ortega B. and Baltimore D. (2004) Mammalian Ryk is a Wnt coreceptor required for stimulation of neurite outgrowth. Cell 119, 97-108.
59. Mao B., Wu W., Li Y., Hoppe D., Stannek P., Glinka A. and Niehrs C. (2001) LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 411, 321-325.
60. McCoy P. A., Shao Y., Wolpert C. M. et al. (2002) No association between the WNT2 gene and autistic disorder. Am. J. Med. Genet. 114, 106-109.
61. Megason S. G. and McMahon A. P. (2002) A mitogen gradient of dorsal midline Wnts organizes growth in the CNS. Development 129, 2087-2098.
62. Mikels A. J. and Nusse R. (2006) Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 4(4), e115.
63. Miyaki M., Seki M., Okamoto M. et al. (1990) Genetic changes and histopathological types in colorectal tumors from patients with familial adenomatous polyposis. Cancer Res. 50, 7166-7173.
64. Miyaoka T., Seno H. and Ishino H. (1999) Increased expression of Wnt- 1 in schizophrenic brains. Schizophr. Res. 38, 1-6.
65. Moon R. T., Kohn A. D., De Ferrari G. V. and Kaykas A. (2004) WNT and beta-catenin signalling: diseases and therapies. Nat. Rev. Genet. 5, 691-701.
66. Nagy Z. (2000) Cell cycle regulatory failure in neurones: causes and consequences. Neurobiol. Aging 21, 761-769.
67. Nagy Z. (2005) The last neuronal division: a unifying hypothesis for the pathogenesis of Alzheimer's disease. J. Cell Mol. Med. 9, 531-541.
68. Neve R. L. and McPhie D. L. (2006) The cell cycle as a therapeutic target for Alzheimer's disease. Pharmacol. Ther. 111, 99-113.
69. Nishimura M., Yu G., Levesque G. et al. (1999) Presenilin mutations associated with Alzheimer disease cause defective intracellular trafficking of beta-catenin, a component of the presenilin protein complex. Nat. Med. 5, 164-169.
70. van Noort M., Meeldijk J., van der Zee R., Destree O. and Clevers H. (2002) Wnt signaling controls the phosphorylation status of betacatenin. J. Biol. Chem. 277, 17901-17905.
71. Parisiadou L., Fassa A., Fotinopoulou A., Bethani I. and Efthimiopoulos S. (2004) Presenilin 1 and cadherins: stabilization of cell-cell adhesion and proteolysis-dependent regulation of transcription. Neurodegener. Dis. 1, 184-191.
72. Pierrot N., Ferrao Santos S., Feyt C., Morel M., Brion J. P. and Octave J. N. (2006) Calcium-mediated transient phosphorylation of tau and amyloid precursor protein followed by intraneuronal amyloidbeta accumulation. J. Biol. Chem. 3, 39907-39914.
73. Quintanilla R. A., Munoz F. J., Metcalfe M. J., Hitschfeld M., Olivares G., Godoy J. A. and Inestrosa N. C. (2005) Trolox and 17betaestradiol protect against amyloid beta-peptide neurotoxicity by a mechanism that involves modulation of the Wnt signaling pathway. J. Biol. Chem. 280, 11615-11625.
74. Raina A. K., Monteiro M. J., McShea A. and Smith M. A. (1999) The role of cell cycle-mediated events in Alzheimer's disease. Int. J. Exp. Pathol. 80, 71-76.
75. Rao A., Luo C. and Hogan P. G. (1997) Transcription factors of the NFAT family: regulation and function. Annu. Rev. Immunol. 15, 707-747.
76. Rees S., Coote J., Stables J., Goodson S., Harris S. and Lee M. G. (1996) Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 20, 102-104, 106, 108-110.
77. Rimm D. L., Caca K., Hu G., Harrison F. B. and Fearon E. R. (1999) Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol. 154, 325-329.
78. Roelen B. A., Lin H. Y., Knezevic V., Freund E. and Mummery C. L. (1994) Expression of TGF-beta s and their receptors during implantation and organogenesis of the mouse embryo. Dev. Biol. 166, 716-728.
79. Scali C., Caraci F., Gianfriddo M. et al. (2006) Inhibition of Wnt signaling, modulation of Tau phosphorylation and induction of neuronal cell death by DKK1. Neurobiol. Dis. 24, 254-265.
80. Schuller U. and Rowitch D. H. (2006) Beta-catenin function is required for cerebellar morphogenesis. Brain Res. 4, 0.
81. Semenov M. V., Tamai K., Brott B. K., Kuhl M., Sokol S. and He X. (2001) Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr. Biol. 11, 951-961.
82. Takashima A., Honda T., Yasutake K., Michel G., Murayama O., Murayama M., Ishiguro K. and Yamaguchi H. (1998) Activation of tau protein kinase I/glycogen synthase kinase-3beta by amyloid beta peptide (25-35) enhances phosphorylation of tau in hippocampal neurons. Neurosci. Res. 31, 317-323.
83. Tamai K., Semenov M., Kato Y., Spokony R., Liu C., Katsuyama Y., Hess F., Saint-Jeannet J. P. and He X. (2000) LDL-receptorrelated proteins in Wnt signal transduction. Nature 407, 530-535.
84. Teo J. L., Ma H., Nguyen C., Lam C. and Kahn M. (2005) Specific inhibition of CBP/beta-catenin interaction rescues defects in neuronal differentiation caused by a presenilin-1 mutation. Proc. Natl Acad. Sci. USA 102, 12171-12176.
85. Tetsu O. and McCormick F. (1999) Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398, 422-426.
86. Vaudry D., Stork P. J., Lazarovici P. and Eiden L. E. (2002) Signaling pathways for PC12 cell differentiation: making the right connections. Science 296, 1648-1649.
87. Wassink T. H., Piven J., Vieland V. J. et al. (2001) Evidence supporting WNT2 as an autism susceptibility gene. Am. J. Med. Genet. 105, 406-413.
88. Winn R. A., Marek L., Han S. Y. et al. (2005) Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation. J. Biol. Chem. 280, 19625-19634.
89. Winn R. A., Van Scoyk M., Hammond M., Rodriguez K., Crossno J. T. Jr, Heasley L. E. and Nemenoff R. A. (2006) Antitumorigenic effect of Wnt 7a and FZD 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 281, 26943-26950.
90. Wu W., Glinka A., Delius H. and Niehrs C. (2000) Mutual antagonism between dickkopf1 and dickkopf2 regulates Wnt/beta-catenin signalling. Curr. Biol. 10, 1611-1614.
91. Zhao C., Aviles C., Abel R. A., Almli C. R., McQuillen P. and Pleasure S. J. (2005) Hippocampal and visuospatial learning defects in mice with a deletion of frizzled 9, a gene in the Williams syndrome deletion interval. Development 132, 2917-2927.
92. Zurawel R. H., Chiappa S. A., Allen C. and Raffel C. (1998) Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res. 58, 896-899.